文献速递胸部肿瘤放疗

IMRT时代剂量递增三联疗法治疗NSCLC的手术并发症与临床结局

Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy.
PubMed 文献 · Radiother Oncol · 2021-10-22

结果显示两组手术并发症、病理完全缓解及术后毒性无显著差异,3年局部区域无复发生存与总生存亦无显著差异。多因素分析中,年龄较大、临床分期及住院时间>7天与总生存相关。

要点

  • IMRT下术前放疗剂量≥60 Gy未增加手术并发症。
  • 两组病理完全缓解及术后毒性无显著差异。
  • 住院时间>7天与更差的总生存相关。

核心结论

  • 采用IMRT时,接受较高放疗剂量的患者手术并发症发生率未增加。
  • 生存结局及住院时间不因放疗剂量不同而存在差异,但住院时间延长与更差的总生存相关。

研究设计与样本

  • 回顾性分析2008至2017年间在Brigham and Women's Hospital/Dana-Farber Cancer Institute接受计划性IMRT三联疗法(TMT)的LA-NSCLC患者。
  • 评估临床与治疗特征、病理反应及手术毒性,采用Kaplan-Meier法和log-rank检验分析生存结局,Cox比例风险回归进行多因素分析。

主要发现

  • 两组手术结局、病理完全缓解及术后毒性无显著差异。
  • 中位随访3.6年(范围0.4-11.4年),<60 Gy组与≥60 Gy组的3年局部区域无复发生存分别为78.0%与68.3%(p=0.51),无显著差异。
  • 两组3年总生存分别为61.0%与69.4%(p=0.32),无显著差异。
  • 多因素分析显示,年龄较大、临床分期及住院时间>7天与总生存相关。

临床怎么用

  • 在IMRT技术下,对LA-NSCLC患者行三联疗法时术前放疗剂量递增至≥60 Gy未显示增加手术并发症。
  • 住院时间>7天提示总生存较差,可作为临床关注因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trimodality therapy (TMT) with preoperative chemoradiation followed by surgical resection is used for locally-advanced non-small-cell lung cancer (LA-NSCLC). Traditionally, preoperative radiation doses ≤54 Gy are used due to concerns regarding excess morbidity, but little is known about outcomes and toxicities after TMT with intensity-modulated radiotherapy (IMRT) to higher doses. METHODS: A retrospective analysis of patients who received planned TMT with IMRT for LA-NSCLC at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2008 and 2017 was performed. Clinical and treatment characteristics, pathologic response, and surgical toxicity were assessed. Kaplan-Meier method and log-rank test was used for survival outcomes. Cox proportional-hazards regression was used for multivariable analysis. RESULTS: Forty-six patients received less than definitive doses of <60 Gy and 30 patients received definitive doses ≥60 Gy. Surgical outcomes, pathologic complete response, and postoperative toxicity did not differ significantly between the groups. With median follow-up of 3.6 years (range: 0.4-11.4), three-year locoregional recurrence-free survival (78.0% vs. 68.3%, p = 0.51) and overall survival (OS) (61.0% vs. 69.4%, p = 0.32) was not significantly different between patients receiving <60 Gy and ≥60 Gy, respectively. On multivariable analysis, older age, clinical stage, and length of hospital stay (LOS) >7 days were associated with OS. CONCLUSIONS: With IMRT, there was no increased rate of surgical complications in patients receiving higher doses of radiation. Survival outcomes or LOS did not differ based on radiation dose, but increased LOS was associated with worse OS. Larger prospective studies are needed to further examine outcomes after IMRT in patients with LA-NSCLC receiving TMT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liu KX, Sierra-Davidson K, Tyan K, et al. Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy. Radiother Oncol. 2021. PMID: 34695520. doi:10.1016/j.radonc.2021.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。